

Leukopenia Management in Thymoglobulin Treated Renal Transplant Recipients

Lynsey S. Biondi MD
Lehigh Valley Health Network, Lynsey_S.Biondi@lvhn.org

Michael J. Moritz MD
Lehigh Valley Health Network, Michael.Moritz@lvhn.org

Janelle Cyprich
Lehigh Valley Health Network, Janelle.Cyprich@lvhn.org

Follow this and additional works at: <https://scholarlyworks.lvhn.org/surgery>



Part of the [Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons](#), [Chemicals and Drugs Commons](#), [Other Medical Specialties Commons](#), and the [Surgery Commons](#)

Let us know how access to this document benefits you

Published In/Presented At

Biondi, L., Moritz, M., & Cyprich, J. (2014, January 23-26). *Leukopenia management in thymoglobulin treated renal transplant recipients*. Poster presented at: The American Society of Transplant surgeons (ASTS) 14th Annual State of the Art Winter Symposium, Miami, FL..

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Leukopenia Management in Thymoglobulin Treated Renal Transplant Recipients

Lynsey A Biondi, MD, Michael J Moritz, MD and Janelle D Cyprich, Department of Surgery
Lehigh Valley Health Network, Allentown, Pennsylvania

Abstract:

Leukopenia is common following renal transplantation, though it is infrequently reported and lacks well-defined management. We retrospectively reviewed 228 consecutive renal transplant recipients at a single center for leukopenia in the first year following transplant. Leukopenic patients were evaluated for treatment strategies, efficacy, and complications including CMV infection, rejection, graft failure, and death. Leukopenia was observed in 43 of 228 (19%) transplants with median onset and duration of 95 days. Ninety-three percent of patients received treatment for leukopenia including Neupogen®, dose reduction of mycophenolic acid (MPA) or valganciclovir, and initiation of prednisone. Grade 2 neutropenia, defined as $ANC \leq 1000$ cells/mm³, had statistically significant increased incidence of CMV ($p < 0.0001$), defined as positive serum PCR, and rejection ($p = 0.013$) compared to non-leukopenic patients. MPA dose reductions $> 50\%$ were associated with higher rates of both CMV (60% v 42%) and rejection (60% v 33%). Conclusions: 1. Leukopenic patients experience significantly increased CMV and rejection. 2. MPA and valganciclovir dose reductions are associated with increased risk of rejection and CMV. 3. Neupogen® is an effective treatment for leukopenia.

Background:

While lymphocyte depleting induction immunosuppression agents are responsible for much of the early post-transplant leukopenia, MPA and valganciclovir have also been linked to a decrease in WBC count and ANC.¹⁻³

Methods:

This retrospective, single-center study included all patients undergoing kidney and/or pancreas transplantation between January 2009 and May 2012. All recipients received thymoglobulin 4-6mg/kg in 3-4 doses and maintenance MPA/tacrolimus. All leukopenic episodes occurring between one month and one year post-transplant were analyzed. Successful treatment of leukopenia was defined as a WBC count of greater than 3500 cells/mm³ for 30 days.


Results:

Leukopenic patients had significantly lower BMI ($p = 0.0152$) than non-leukopenic patients, but matched in age, gender, transplant type, and PRA. Interventions for leukopenia were not standardized.

Severely neutropenic patients had a statistically significant increased incidence of CMV ($p < 0.0001$) compared with non-leukopenic patients. Of the 20 leukopenic patients who developed CMV, 10/20 (50%) developed CMV prior to leukopenia. Compared with full dose valganciclovir, dose reduction was associated with a higher rate of CMV (77% v 37%) $p = 0.021$. Only 4 of 10 had dose reduction prior to the CMV infection.

Neutropenic patients also had a statistically significant increase in rejection ($p = 0.013$) compared with non-leukopenic patients. 11/17 (65%) leukopenic patients experienced rejection after treatment of leukopenia.

While greater degrees of MPA dose reduction resulted in a shorter median duration of leukopenia (110 v 74 days), greater MPA dose reductions were also associated with higher rates of CMV and rejection (see graph).



Of the 4 patients who received Neupogen® without any medication dose reductions, only 1 experienced rejection and CMV. Neupogen® took the shortest amount of time to recover WBC count (29 days) compared to prednisone (71 days), MPA dose reductions (55 days), and valganciclovir dose reduction (35 days). It is difficult to attribute improvement in leukopenia to one treatment given the multifactorial treatment process.

Conclusions:


1. Leukopenic patients experience significantly increased CMV and rejection.
2. MPA and valganciclovir dose reductions are associated with an increased risk of rejection and CMV.
3. Neupogen® is an effective treatment for leukopenia.

References:

1 Hartmann, E. L., et al. (2008). Management of leukopenia in kidney and pancreas transplant recipients. *Clinical transplantation*, 22(6), 822-828.
2 Brum, S., et al. (2008, April). Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. In *Transplantation proceedings* (Vol. 40, No. 3, pp. 752-754). Elsevier.
3 Zafrani, L., et al. (2009). Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. *American Journal of Transplantation*, 9(8), 1816-1825.

© 2014 Lehigh Valley Health Network

Outcomes in Leukopenic vs. Non-Leukopenic Patients



Grade 1 Neutropenia ($1000 \text{ cells/mm}^3 < ANC \leq 1500 \text{ cells/mm}^3$), and **Grade 2** Neutropenia ($ANC \leq 1000 \text{ cells/mm}^3$).